In a mouse model of non-alcoholic fatty liver disease (NAFLD), it has been demonstrated that metformin decreases hepatic steatosis and insulin resistance, promoting TFEB-dependent autophagy [60]. Here, TFEB is linked to metabolic dysfunction-associated steatotic liver disease.